

Press release from Emotra AB (publ)

Göteborg, October 12, 2015

Flagging notice for shares in Emotra AB

Following its new share issue with right of priority that was completed on October 7, 2015, Emotra AB is making the following flagging announcement:

Lars-Håkan Thorell and related persons hold an unchanged amount of 1,290,976 shares in Emotra AB, which after completion of this rights issue will be equal to about 13.56% of the votes and capital in the Company (a decrease from appr. 24.87% before this new share issue).

For further information, please contact:

Claes Holmberg, CEO

Telephone: +46 708 25 45 47

E-mail: claes@emotra.se

Emotra AB (publ) is a medical technology company that carries out research, development, clinical studies and marketing in the area of suicide prevention. The Company's method, EDOR, is a proprietary, objective and quantitative diagnostic, psychophysiological test for detecting hyporeactivity in patients suffering from depression. During the test, the patient listens to a series of audio signals. The patient's response, in the form of very small changes in dermal electric conductivity, is measured and analysed. This extremely sensitive and specific test of suicidal risk has been developed as the result of research.

Emotra AB (publ), Göteborgsvägen 74, SE-433 63 Sävedalen, Sweden

Tel: +46 708 25 45 47, www.emotra.se